Active, Not Recruiting
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer - CA018-003
Updated:
30 November, 2022
|
ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Inoperable, advanced or metastatic esophageal cancer (EC), gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have histologically confirmed predominant adenocarcinoma and/or squamous carcinoma - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 - At least 1 lesion with measurable disease Exclusion Criteria: - HER2-positive tumor and previously untreated with trastuzumab - Suspected, known or progressive central nervous system metastases - Other active malignancy requiring concurrent intervention - Active, known or suspected autoimmune disease Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information